GlaxoSmithKline PLC (NYSE:GSK) – Analysts at Jefferies Group decreased their FY2016 earnings per share (EPS) estimates for shares of GlaxoSmithKline PLC in a research report issued on Thursday. Jefferies Group analyst J. Holford now forecasts that the firm will earn $2.44 per share for the year, down from their prior estimate of $2.64. Jefferies Group has a “Buy” rating on the stock. Jefferies Group also issued estimates for GlaxoSmithKline PLC’s FY2017 earnings at $2.59 EPS, FY2018 earnings at $2.77 EPS, FY2019 earnings at $3.07 EPS and FY2020 earnings at $3.38 EPS.

Earnings History and Estimates for GlaxoSmithKline PLC (NYSE:GSK)

Several other analysts have also weighed in on GSK. Zacks Investment Research raised GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a report on Tuesday, June 21st. Shore Capital reissued a “hold” rating on shares of GlaxoSmithKline PLC in a report on Tuesday, June 21st. Beaufort Securities reissued a “buy” rating on shares of GlaxoSmithKline PLC in a report on Tuesday, June 21st. Bank of America Corp. reissued a “buy” rating and issued a $48.00 price objective on shares of GlaxoSmithKline PLC in a report on Wednesday, June 22nd. Finally, Citigroup Inc. reissued a “buy” rating on shares of GlaxoSmithKline PLC in a report on Thursday, June 23rd. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. GlaxoSmithKline PLC currently has a consensus rating of “Hold” and an average price target of $47.86.

GlaxoSmithKline PLC (NYSE:GSK) opened at 41.19 on Monday. GlaxoSmithKline PLC has a 52 week low of $37.82 and a 52 week high of $45.58. The stock’s 50 day moving average price is $43.08 and its 200-day moving average price is $42.97. The stock has a market capitalization of $100.11 billion, a P/E ratio of 2574.37 and a beta of 0.88.

Large investors have recently added to or reduced their stakes in the company. FMR LLC boosted its position in GlaxoSmithKline PLC by 29.8% in the second quarter. FMR LLC now owns 20,701,378 shares of the pharmaceutical company’s stock valued at $897,198,000 after buying an additional 4,757,238 shares in the last quarter. Fisher Asset Management LLC boosted its position in GlaxoSmithKline PLC by 1.1% in the third quarter. Fisher Asset Management LLC now owns 11,861,172 shares of the pharmaceutical company’s stock valued at $511,572,000 after buying an additional 130,297 shares in the last quarter. State Street Corp boosted its position in GlaxoSmithKline PLC by 1.1% in the second quarter. State Street Corp now owns 10,472,620 shares of the pharmaceutical company’s stock valued at $453,884,000 after buying an additional 111,349 shares in the last quarter. Bank of New York Mellon Corp boosted its position in GlaxoSmithKline PLC by 0.6% in the second quarter. Bank of New York Mellon Corp now owns 5,976,687 shares of the pharmaceutical company’s stock valued at $259,030,000 after buying an additional 35,788 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its position in GlaxoSmithKline PLC by 24.7% in the second quarter. Ameriprise Financial Inc. now owns 3,038,134 shares of the pharmaceutical company’s stock valued at $132,800,000 after buying an additional 602,693 shares in the last quarter. Hedge funds and other institutional investors own 8.80% of the company’s stock.

The company also recently announced a dividend, which was paid on Thursday, October 13th. Shareholders of record on Friday, August 12th were given a $0.494 dividend. The ex-dividend date was Wednesday, August 10th. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is 6,166.67%.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

5 Day Chart for NYSE:GSK

Receive News & Stock Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related stocks with our FREE daily email newsletter.